Global Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Industry Insights: Key Trends and Growth Estimates
Uncover key drivers, emerging technologies, and competitive movements shaping the cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market from 2026–2035 with trusted insights from The Business Research Company
How much larger will the Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market be in 2030 compared with 2026?
The market size for cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing has expanded considerably in recent years. It is anticipated to increase from $1.06 billion in 2025 to $1.22 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 14.6%. This historical growth can be attributed to several factors including broader coverage of cervical cancer screening programs, the incorporation of molecular diagnostics in gynecology, heightened awareness regarding high-risk HPV infection dangers, the availability of automated PCR platforms, and the establishment of more centralized diagnostic laboratories.
The cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market size is anticipated to experience substantial growth in the coming years, projected to reach $2.12 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.9%. This expansion throughout the forecast period stems from factors such as a growing inclination towards primary HPV screening, an increasing need for high-specificity cancer risk stratification, the broadening of population-based screening programs, the incorporation of digital pathology and reporting systems, and escalating investments in precision diagnostics. Key trends influencing this period include the wider acceptance of mRNA-based primary cervical screening assays, the expanding utilization of fully automated molecular testing platforms, the increasing integration of genotype-specific reflex testing, the development of high-specificity screening algorithms, and a heightened focus on clinically actionable HPV detection.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=33060&type=smp
What Drivers Are Guiding Growth Patterns In The Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market?
The cervical human papillomavirus messenger ribonucleic acid testing market is anticipated to expand due to the growing incidence of cervical cancer. Cervical cancer, a malignant condition originating in cervical cells, is primarily caused by persistent high-risk human papillomavirus infections and remains a major contributor to cancer-related morbidity and mortality among women globally. The rise in cervical cancer prevalence is often attributed to inadequate cervical screening participation, which delays detection and allows persistent human papillomavirus infections to progress into cancer. Cervical human papillomavirus messenger ribonucleic acid testing facilitates the detection of active high-risk human papillomavirus infections, thus enhancing risk assessment and supporting prompt interventions to slow cervical cancer progression. An illustration of this trend comes from Cancer Australia, a government agency based in Australia, which reported that while there were 265 deaths from cervical cancer in Australia in 2023, an estimated 254 deaths are projected for 2025. Consequently, the increasing occurrence of cervical cancer is fueling the expansion of the cervical human papillomavirus messenger ribonucleic acid testing market.
How Is The Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Divided Into Segments?
The cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market covered in this report is segmented –
1) By Product Type: Assay Kits; Instruments; Reagents And Consumables
2) By Application: Cervical Cancer Screening; Research; Other Applications
3) By End User: Hospitals And Clinics; Diagnostic Laboratories; Research Institutes; Other End Users
Subsegments:
1) By Assay Kits: Messenger Ribonucleic Acid Detection Kits; Multiplex Testing Kits; High Risk Genotype Specific Kits; Screening And Diagnostic Kits
2) By Instruments: Real Time Polymerase Chain Reaction Systems; Automated Molecular Analyzers; Sample Preparation Systems; Nucleic Acid Extraction Instruments
3) By Reagents And Consumables: Primers And Probes; Enzymes And Buffers; Controls And Standards; Extraction And Purification Consumables
Which Market Trends Are Opening Growth Opportunities In The Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market?
Companies operating within the cervical human papillomavirus messenger ribonucleic acid (mRNA) testing market are prioritizing the development of technological advancements, particularly multiplex real-time PCR innovations, to achieve a competitive edge. This focus aims to enhance diagnostic precision, facilitate concurrent E6/E7 mRNA identification and high-risk HPV genotype analysis, minimize false positive results, decrease testing expenses, and broaden adoption. Multiplex real-time PCR innovations refer to the capability to simultaneously identify and measure multiple HPV E6/E7 mRNA targets and high-risk genotypes within a single PCR reaction, thus boosting the accuracy, effectiveness, and clinical relevance of cervical HPV testing. For example, in July 2024, Medicon Hellas S.A., a diagnostics firm based in Greece, launched a multiplex real-time PCR kit for HPV E6/E7 mRNA genotyping, acting as the sole distributor for Uni-Medica in Greece and Cyprus. This kit offers features such as compatibility with various PCR instruments, including Bio-Rad CFX96 and Hongshi SLAN-96 series, for fluorochrome analysis using CT values. It is also applicable to a wide array of samples, such as semen, urine, and anal swabs, extending beyond traditional cytology. Moreover, it holds CE-IVD marking and delivers results within 2.5 hours.
Which Major Industry Participants Are Leading The Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Growth?
Major companies operating in the cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Becton, Dickinson and Company, Eurofins Scientific, Agilent Technologies Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Bio-Techne Corporation, Co-Dx Ltd., Promega Corporation, Seegene Inc., Molbio Diagnostics, QIAGEN N.V., Sansure Biotech Inc., Xiamen Zeesan Biotech Co. Ltd., DiaCarta Inc., Operon S.A., AB ANALITICA s.r.l., Arbor Vita Corporation, Mylab Discovery Solutions, Guangdong Hybribio Biotech Co. Ltd., Atila Biosystems, GeneFirst Ltd., Advanced Molecular Diagnostics.
Access The Complete Report For Deeper Market Insights:
Which Region Is Expected To Experience The Fastest Growth In The Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market?
North America was the largest region in the cervical human papillomavirus (HPV) messenger ribonucleic acid (mRNA) testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=33060&type=smp
Browse Through More Reports Similar to the Global Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market 2026, By The Business Research Company
Human Papillomavirus Hpv Vaccine Market Report 2026
Hpv Testing And Pap Test Market Report 2026
https://www.thebusinessresearchcompany.com/report/hpv-testing-and-pap-test-global-market-report
Hpv Associated Disorders Market Report 2026
https://www.thebusinessresearchcompany.com/report/hpv-associated-disorders-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
